Drug profile · INN
aminosalicylate sodium
P.A.S. SODIUM
aminosalicylate sodium (P.A.S. SODIUM) is a dihydrofolate reductase inhibitor. Associated with Solid Biosciences. Route of administration: oral. Current US regulatory status: approved.
Drug details — aminosalicylate sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
aminosalicylate sodium (P.A.S. SODIUM) is a dihydrofolate reductase inhibitor. Associated with Solid Biosciences. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is aminosalicylate sodium?
aminosalicylate sodium (P.A.S. SODIUM) is a dihydrofolate reductase inhibitor. Associated with Solid Biosciences. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for aminosalicylate sodium?
P.A.S. SODIUM is a marketed brand name for aminosalicylate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aminosalicylate sodium?
aminosalicylate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.